Effect of Aromatase Inhibitors for Preventing Ovarian Hyperstimulation Syndrome in Infertile Patients Undergoing in Vitro Fertilization: a Systematic Review and Meta-analysis

Overview

Journal Reprod Biol Endocrinol

Publisher Biomed Central

Specialties Endocrinology
Reproductive Medicine

Date 2024 Jul 23

PMID 39044268

Authors

Linying Jiang

Yuhan Qiu

Lijuan Xu

Ruiqi Chang

Fan He

Affiliations

Soon will be listed here.

Abstract

Purpose: To summarize the findings of relevant randomized controlled trials (RCTs) and conduct a meta-analysis to investigate the potential effect of aromatase inhibitors on preventing moderate to severe ovarian hyperstimulation syndrome (OHSS) in infertile women undergoing in vitro fertilization (IVF).

Methods: We searched for relevant RCTs in electronic databases, including MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov (from inception to August 2023). In addition, we manually searched the related reviews and reference lists of included studies for further relevant studies. We included RCTs where aromatase inhibitors prescribed either during controlled ovarian stimulation (COS) or in early luteal phase. The meta-analysis was performed using RevMan 5.4.1 software. The primary outcome was the incidence of moderate to severe OHSS. A descriptive analysis was conducted in cases where a meta-analysis was not feasible due to heterogeneity or lack of comparable data.

Results: 2858 records were retrieved and 12 RCTs were finally included. Letrozole was administered in the treatment group during COS in seven RCTs, whereas in the early luteal phase in five RCTs. Compared with the control group, the risk of moderate to severe OHSS significantly reduced by 55% in the letrozole group (RR 0.45, 95% CI 0.32 to 0.64, I = 0%, 5 RCTs, 494 patients). Moreover, serum estradiol (E2) levels on hCG trigger day significantly decreased with the administration of letrozole during COS (MD -847.23, 95% CI -1398.00 to -296.47, I = 93%, 5 RCTs, 374 patients). And serum E2 levels on the 4th, 5th and 7th to 10th day after hCG trigger were also significantly lower than those in the control group when letrozole was administered in the early luteal phase.

Conclusions: Patients with high risk of OHSS probably benefit from letrozole, which has been revealed to reduce the incidence of moderate to severe OHSS by this systematic review. However, the very limited number of participants and the quality of the included studies does not allow to recommend letrozole for the prevention of severe OHSS.

References

Yang X, Lin G, Lu G, Gong F . Letrozole supplementation during controlled ovarian stimulation in expected high responders: a pilot randomized controlled study. Reprod Biol Endocrinol. 2019; 17(1):43. PMC: 6511177. DOI: 10.1186/s12958-019-0483-x. View

Choudhary R, Vora P, Darade K, Pandey S, Ganla K . A Prospective Randomised Comparative Clinical Trial Study of Luteal PhaseLetrozole versus Ganirelix Acetate Administration to Prevent Severity of Early Onset OHSS in ARTs. Int J Fertil Steril. 2021; 15(4):263-268. PMC: 8530210. DOI: 10.22074/IJFS.2021.139562.1042. View

He Q, Liang L, Zhang C, Li H, Ge Z, Wang L . Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med. 2014; 60(6):355-60. DOI: 10.3109/19396368.2014.957879. View

Mourad S, Brown J, Farquhar C . Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017; 1:CD012103. PMC: 6469542. DOI: 10.1002/14651858.CD012103.pub2. View

Guo J, Zhang D, Zhao Y, Zhang D, Zhang X, Zhou C . Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis. Sci Rep. 2016; 6:19093. PMC: 4707491. DOI: 10.1038/srep19093. View

Aronica S, Kraus W, Katzenellenbogen B . Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A. 1994; 91(18):8517-21. PMC: 44637. DOI: 10.1073/pnas.91.18.8517. View

Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E . Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989; 44(6):430-40. DOI: 10.1097/00006254-198906000-00004. View

Jin P, Lu Y, Li L, Han Q . Co action of CFTR and AQP1 increases permeability of peritoneal epithelial cells on estrogen-induced ovarian hyper stimulation syndrome. BMC Cell Biol. 2012; 13:23. PMC: 3443456. DOI: 10.1186/1471-2121-13-23. View

Tshzmachyan R, Hambartsoumian E . The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study. J Gynecol Obstet Hum Reprod. 2019; 49(2):101643. DOI: 10.1016/j.jogoh.2019.101643. View

10.

Eftekhar M, Saeed L . Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: An RCT. Int J Reprod Biomed. 2020; 18(4):287-294. PMC: 7218674. DOI: 10.18502/ijrm.v13i4.6891. View

11.

. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016; 106(7):1634-1647. DOI: 10.1016/j.fertnstert.2016.08.048. View

12.

Garcia-Velasco J, Quea G, Piro M, Mayoral M, Ruiz M, Toribio M . Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril. 2008; 92(1):222-5. DOI: 10.1016/j.fertnstert.2008.04.042. View

13.

Namavar Jahromi MD B, Parsanezhad MD M, Shomali MD Z, Bakhshai MD P, Alborzi MD M, Moin Vaziri MD PhD N . Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. Iran J Med Sci. 2018; 43(3):248-260. PMC: 5993897. View

14.

Zhao J, Xu B, Huang X, Yan Y, Li Y . Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis. Reprod Health. 2020; 17(1):181. PMC: 7678310. DOI: 10.1186/s12978-020-01042-2. View

15.

Fatemi H, Popovic-Todorovic B, Donoso P, Papanikolaou E, Smitz J, Devroey P . Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reprod Biomed Online. 2008; 17(3):307-11. DOI: 10.1016/s1472-6483(10)60212-x. View

16.

Mukherjee S, Sharma S, Chakravarty B . Letrozole in a low-cost in vitro fertilization protocol in intracytoplasmic sperm injection cycles for male factor infertility: A randomized controlled trial. J Hum Reprod Sci. 2012; 5(2):170-4. PMC: 3493831. DOI: 10.4103/0974-1208.101014. View

17.

Agrawal R, Tan S, Wild S, Sladkevicius P, Engmann L, Payne N . Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 1999; 71(2):287-93. DOI: 10.1016/s0015-0282(98)00447-6. View

18.

Carrageta D, Bernardino R, Alves M, Oliveira P . CFTR regulation of aquaporin-mediated water transport. Vitam Horm. 2020; 112:163-177. DOI: 10.1016/bs.vh.2019.08.004. View

19.

Luo J, Qi Q, Chen Y, Wang Y, Xie Q . Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model. Reprod Biomed Online. 2020; 42(2):291-300. DOI: 10.1016/j.rbmo.2020.10.006. View

20.

Henriquez S, Kohen P, Xu X, Veenstra T, Munoz A, Palomino W . Estrogen metabolites in human corpus luteum physiology: differential effects on angiogenic activity. Fertil Steril. 2016; 106(1):230-237.e1. DOI: 10.1016/j.fertnstert.2016.03.003. View